Every day, roughly 2,000 bags of donated blood arrive at a vast NHS facility, initiating a remarkable 27-hour race against time. This isn’t simply about storing blood; it’s about unlocking its hidden potential to save and dramatically improve lives.
While red blood cells are crucial for trauma victims and surgical patients, a lesser-known component holds extraordinary power: plasma. Often called “liquid gold” due to its pale yellow hue, plasma is a complex fluid brimming with vital antibodies – the building blocks of life-saving medicines.
The journey begins with filtering each 470ml donation, removing white blood cells. Then, the blood is spun at incredible speeds within a powerful centrifuge. This separates the plasma from the red blood cells, a visual transformation revealing the golden liquid within.
Red blood cells are carefully stored at 4°C, awaiting safety tests conducted in Bristol before being dispatched to hospitals. Donors are even notified via text message when their blood helps someone in need. But the plasma’s path is far from over.
Plasma destined for immediate use in treating severe bleeding is rapidly frozen at -20°C. However, the most promising plasma undergoes an even deeper freeze, plummeting to a staggering -40°C – a temperature requiring specialized protective gear for those who handle it.
This ultra-cold preservation is essential because plasma is the key ingredient in creating immunoglobulins, medicines that treat over 50 devastating autoimmune conditions. It also yields albumins, vital for treating severe burns and traumatic injuries, benefiting more than 17,000 people annually.
For 25 years, a ban stemming from concerns about ‘mad cow’ disease prevented the use of British plasma for these medicines. But in March of last year, a historic milestone was reached: the first immunoglobulin derived from a UK donor was administered to an NHS patient.
Currently, the UK relies heavily on imported plasma for medicine production. The frozen plasma awaits transport to European facilities, a process requiring swift action and specialized mobile freezers. Since March 2025, thousands of patients have benefited from these life-saving, British-sourced treatments.
Despite this progress, the UK remains over 75% reliant on immunoglobulin from other countries. Jan Majkowski, a lead specialist at the processing hub, emphasizes the critical role of plasma: “These fractions are invaluable, treating both rare and common diseases. For many, these transfusions are their only support.”
Beyond immunoglobulins, plasma yields clotting factors for bleeding disorders like haemophilia, created through a painstaking 16-hour thawing process. Even platelets, tiny blood fragments, are extracted and used in cancer treatments and surgical procedures, kept viable through constant agitation.
Approximately 800,000 people donate blood each year, yet a shortfall of over 200,000 donors persists. The NHS urgently needs more donors, particularly those of Black heritage, who are more likely to possess the Ro blood subtype vital for treating sickle cell disorder – a condition prevalent within those communities.
The Colindale hub operates around the clock, staffed by 80 dedicated employees. Every bag of blood, every drop of plasma, represents a potential lifeline, a testament to the power of human generosity and the relentless pursuit of medical advancement.
